for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Henan Lingrui Pharmaceutical Co., Ltd.

600285.SS

Latest Trade

8.44CNY

Change

-0.10(-1.17%)

Volume

7,175,900

Today's Range

8.39

 - 

8.60

52 Week Range

6.81

 - 

10.68

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
8.54
Open
8.54
Volume
7,175,900
3M AVG Volume
131.81
Today's High
8.60
Today's Low
8.39
52 Week High
10.68
52 Week Low
6.81
Shares Out (MIL)
586.45
Market Cap (MIL)
4,949.63
Forward P/E
15.63
Dividend (Yield %)
1.78

Latest Developments

More

Henan Lingrui Pharmaceutical's Chairman Resigns Due To Personal Reasons

Henan Lingrui Pharmaceutical Plans Share Buyback Worth Up To 300 Mln Yuan

Henan Lingrui Pharmaceutical to pay FY 2017 annual div on June 7

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Henan Lingrui Pharmaceutical Co., Ltd.

Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.

Industry

Biotechnology & Drugs

Contact Info

No.666, Jiangjun Road, Xin County

+86.376.2973569

http://www.lingrui.com

Executive Leadership

Jianjun Cheng

Chairman of the Board

Zirun Pan

Chief Financial Officer

Wei Xiong

General Manager

Xizhen Wu

Deputy General Manager, Director

Yan Chen

Deputy General Manager

Key Stats

1.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

1.4K

2017

1.8K

2018

2.1K

2019(E)

2.3K
EPS (CNY)

2016

0.600

2017

0.370

2019(E)

0.540
Price To Earnings (TTM)
18.35
Price To Sales (TTM)
2.38
Price To Book (MRQ)
2.24
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
11.92
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
11.78
Return on Equity (TTM)
7.76

Latest News

BRIEF-Henan Lingrui Pharmaceutical To Buy Back 300 Million Yuan Worth Of Company Shares

* SAYS IT PLANS TO BUY BACK 300 MILLION YUAN WORTH OF COMPANY SHARES AT UP TO 9 YUAN PER SHARE WITHIN SIX MONTHS Source text for Eikon: http://bit.ly/2E3CC1r Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Henan Lingrui Pharmaceutical passes review of high-tech enterprise recognition

* Says it passed the review of high-tech enterprise recognition and will enjoy a tax preference of 15 percent for three years

BRIEF-Henan Lingrui Pharmaceutical unit obtains high-tech enterprise recognition

* Says its unit will enjoy tax preference of 15 percent for three years from Aug. 10

BRIEF-Henan Lingrui Pharmaceutical receives GMP certificate

* Says it received goods manufacture practice (GMP) certificate from Henan Food and Drug Administration

BRIEF-Henan Lingrui Pharma reduces stakes in Jiangsu Yabang to 2.78 pct

* Says it has unloaded 16 million shares in Jiangsu Yabang Dyestuff Ltd between July 22 and September 27, reducing stake to 2.78 percent from 5.56 percent

BRIEF-Henan Lingrui Pharmaceutical to pay 2016 H1 div on Sept. 13

* Says it will pay cash dividend of 1.5 yuan per 10 shares (before tax) to shareholders for 2016 H1 as a record of Sept. 12

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up